NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 107 filers reported holding NGM BIOPHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.50 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,519 | -48.6% | 28,522 | +24.4% | 0.00% | – |
| Q2 2023 | $59,397 | -31.5% | 22,933 | +8.0% | 0.00% | – |
| Q1 2023 | $86,651 | -11.2% | 21,238 | +9.2% | 0.00% | – |
| Q4 2022 | $97,615 | -87.9% | 19,445 | -68.6% | 0.00% | – |
| Q3 2022 | $809,000 | +16.7% | 61,903 | +14.7% | 0.00% | – |
| Q2 2022 | $693,000 | -17.7% | 53,980 | -2.3% | 0.00% | – |
| Q1 2022 | $842,000 | -8.5% | 55,238 | +6.4% | 0.00% | – |
| Q4 2021 | $920,000 | -11.0% | 51,925 | +5.5% | 0.00% | – |
| Q3 2021 | $1,034,000 | +249.3% | 49,195 | +228.2% | 0.00% | – |
| Q2 2021 | $296,000 | -70.7% | 14,991 | -56.9% | 0.00% | – |
| Q1 2021 | $1,011,000 | -56.8% | 34,766 | -55.0% | 0.00% | -100.0% |
| Q4 2020 | $2,338,000 | +234.0% | 77,178 | +75.3% | 0.00% | – |
| Q3 2020 | $700,000 | -6.3% | 44,017 | +16.3% | 0.00% | – |
| Q2 2020 | $747,000 | – | 37,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $232,513,000 | 49.48% |
| Ponoi II Management, LLC | 1,298,908 | $16,652,000 | 45.25% |
| Ponoi Management, LLC | 1,298,908 | $16,652,000 | 26.29% |
| Euclidean Capital LLC | 746,674 | $9,572,000 | 8.14% |
| StepStone Group LP | 1,573,357 | $20,170,000 | 2.16% |
| First Light Asset Management, LLC | 1,135,884 | $14,562,000 | 1.69% |
| Lexington Partners L.P. | 110,428 | $1,416,000 | 0.73% |
| Rubric Capital Management LP | 797,588 | $10,225,000 | 0.54% |
| Boxer Capital, LLC | 500,000 | $6,410,000 | 0.41% |
| DAFNA Capital Management LLC | 107,653 | $1,380,000 | 0.38% |